Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
October 27, 2021 at 04:30 am EDT
Share
Shenzhen New Industries Biomedical Engineering Co., Ltd. reported earnings results for the nine months ended September 30, 2021. For the nine months, the company reported sales was CNY 1,893.88 million compared to CNY 1,570.38 million a year ago. Revenue was CNY 1,893.88 million compared to CNY 1,570.38 million a year ago. Net income was CNY 665.72 million compared to CNY 698.37 million a year ago. Basic earnings per share from continuing operations was CNY 0.8491 compared to CNY 0.9441 a year ago. Diluted earnings per share from continuing operations was CNY 0.8486 compared to CNY 0.9441 a year ago.
Shenzhen New Industries Biomedical Engineering Co Ltd is a company engaged in research and development, production and sales of in-vitro diagnostics instruments and supporting reagents. The Company operates three segments, including Instruments and Supporting Software, Reagents, Accessories and Others. Instruments and Supporting Software segment is involved in the production and sales of MAGLUMI automatic chemiluminescence immunoassay analyzer series products and Biossays automatic biochemical analyzer series products. Reagents segment operates the sales of supporting reagents for the analyzers. The products are applied in the examination of Gonads, thyroid gland, glucose metabolism, kidney function and so on. Accessories and Others segment is responsible for the manufacturing and sales of accessories related to in-vitro diagnostics equipment. The Company sells its products both in domestic and international markets, including Asia, Europe, America and Africa.